UroToday22h
ASCO GU 2025: Management of Biochemical Recurrence after Radiation Therapy for Localized Prostate Cancer: Reirradiation, Brachytherapy and SBRT.
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Case-Based Session: Management of Biochemical ...
UroToday22h
ASCO GU 2025: Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA was host to the prostate cancer poster session. Dr. Andrei Gafita ...
UroToday22h
ASCO GU 2025: Recurrence after Radiation Therapy: Evaluation, Management, and Outcomes
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Case-Based Session: Management of Biochemical ...
UroToday22h
ASCO GU 2025: Efficacy of 177Lu-PSMA-617 with or Without Androgen Receptor Pathway Inhibitors for the Treatment of mCRPC: VISION Secondary Analysis
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Omid Yazdanpanah discussing a secondary analysis of the VISION trial assessing the efficacy ...